Home

NORBERT G RIEDEL

CIK 1161662 · EXECUTIVE CHAIRMAN OF THE BOD · last filed 2026-09-02

NORBERT G RIEDEL is an EXECUTIVE CHAIRMAN OF THE BOD who has filed 86 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider had shares withheld for taxes covering $411.9K of JAZZ on Sep 2, 2026. Across all open-market trades the lifetime net is −$28.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $18.9M across reported positions. 49 SEC filings were submitted jointly with BAXTER INTERNATIONAL INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$18.88M

Companies

8

Total Filings

86

Lifetime Open-Market Net

-$28.05M

Filer Profile

Reported Address
C/O JAZZ PHARMACEUTICALS, INC.
3000 EL CAMINO REAL, 2 PALO ALTO SQUARE
PALO ALTO, CA 94306
Related Filers
BAXTER INTERNATIONAL INC — 49 joint filings, latest 2013-01-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
JAZZ Director 19,245 $245.80 $4.73M -$3.30M 21 2026-09-02
ETON Director 224,300 $57.08 $12.80M $30.0K 13 2026-08-04
Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Director 56,553 $44.96 $2.54M $0 4 2024-06-07
Aptinyx Inc. (APTX) Delisted EXECUTIVE CHAIRMAN OF THE BOD 650,265 $0.06 $39.7K $366.4K 13 2023-01-05
Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted Director 28,540 $18.07 $515.7K $0 2 2021-06-14
ARIAD PHARMACEUTICALS INC (ARIA) Delisted Director 0 — — $0 8 2017-02-16
BAX Corporate Vice President 56,689 $23.80 $1.35M -$25.15M 17 2013-01-18
OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted Director 1,340 — — $0 2 2008-06-13

Recent Filings

86 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 JAZZ Tax (F) −1,706 -$411.9K EDGAR
2026-08-31 JAZZ Notice (144) −3,507 -$857.6K EDGAR
2026-08-07 JAZZ Grant (A) +1,605 $0 EDGAR
2026-08-07 JAZZ Grant (A) +1,605 $0 EDGAR
2026-08-04 ETON Grant (A) — $0 EDGAR
2026-04-22 ETON Exer (M) +32,155 $260.6K EDGAR
2026-03-02 JAZZ Mixed — -$184.1K EDGAR
2026-02-27 JAZZ Notice (144) −3,415 -$655.7K EDGAR
2026-02-05 ETON Exer (X) +30,000 $132.6K EDGAR
2026-01-14 ETON Grant (A) — $0 EDGAR
Showing 1–10 of 86
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.